Thera-SAbDab

RELATLIMAB

>   Structural Summary
TherapeuticRelatlimab
TargetLAG3
Heavy ChainQVQLQQWGAGLLKPSETLSLTCAVYGGSFSDYYWNWIRQPPGKGLEWIGEINHRGSTNSNPSLKSRVTLSLDTSKNQFSLKLRSVTAADTAVYYCAFGYSDYEYNWFDPWGQGTLVTVSS
Light ChainEIVLTQSPATLSLSPGERATLSCRASQSISSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPLTFGQGTNLEIK
100% seqID Fv StructureNone
99% seqID Fv Structure7um3 [Fvs: HL, IM]
95-98% seqID Fv StructureNone
>   Alignments

Non-identical sequences have been numbered using the Chothia scheme and aligned to Relatlimab.
CDR positions are indicated in blue. Mismatching positions are highlighted in orange.

Sequence identity: 99.12%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 100C 100D 101 102 103 104 105 106 107 108 109 110 111 112 113
relatlimab Q V Q L Q Q W G A G L L K P S E T L S L T C A V Y G G S F S D Y Y W N W I R Q P P G K G L E W I G E I N H R G S T N S N P S L K S R V T L S L D T S K N Q F S L K L R S V T A A D T A V Y Y C A F G Y S D Y E Y N W F D P W G Q G T L V T V S S
7um3 Q V Q L Q Q W G A G L L K P S E T L S L T C A V Y G G S F S D Y Y W N W I R Q P P G K G L E W I G E I N H N G N T N S N P S L K S R V T L S L D T S K N Q F S L K L R S V T A A D T A V Y Y C A F G Y S D Y E Y N W F D P W G Q G T L V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
relatlimab E I V L T Q S P A T L S L S P G E R A T L S C R A S Q S I S S Y L A W Y Q Q K P G Q A P R L L I Y D A S N R A T G I P A R F S G S G S G T D F T L T I S S L E P E D F A V Y Y C Q Q R S N W P L T F G Q G T N L E I K
7um3 E I V L T Q S P A T L S L S P G E R A T L S C R A S Q S I S S Y L A W Y Q Q K P G Q A P R L L I Y D A S N R A T G I P A R F S G S G S G T D F T L T I S S L E P E D F A V Y Y C Q Q R S N W P L T F G Q G T N L E I K
>   Metadata
FormatWhole mAb
IsotypeG4
Highest Clinical Trial (August '23)Approved
Estimated Status (August '23)Active
Recorded Developmental Technologyna
INN Year Proposed2018
INN Year Recommended2019
Companies InvolvedBristol-Myers Squibb, Ono Pharmaceutical, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Conditions ApprovedMalignant melanoma
Conditions ActiveColorectal cancer, Gastric cancer, Renal cell carcinoma, Solid tumours, Oesophageal cancer, Glioblastoma
Conditions DiscontinuedChronic lymphocytic leukaemia, Diffuse large B cell lymphoma, Hodgkin's disease, Mantle-cell lymphoma, Non-Hodgkin's lymphoma
Notes

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]

Our privacy policy